Abivax (ABVX)

Executive Summary

Abivax (Euronext: ABVX) is a clinical-stage biotechnology company focused on developing novel therapies that modulate the immune system via microRNA targeting. Its lead candidate, obefazimod (ABX464), is being evaluated for moderately to severely active ulcerative colitis (UC). The drug has a unique mechanism of action that upregulates a key microRNA, leading to anti-inflammatory effects. Positive Phase 2b results have been reported, and the company has advanced obefazimod into Phase 3 development. Abivax recently completed a Phase 3 trial (NCT05507203) in June 2025 and has an ongoing Phase 3 study (NCT05177835) expected to complete in April 2026. The company also has earlier-stage programs in rheumatoid arthritis and other indications. With a market cap of ~€8.8B, Abivax is a mid-cap biotech with significant upside potential if obefazimod succeeds in UC. Upcoming catalysts include data from the ongoing Phase 3 trial, potential regulatory submissions, and possible partnership announcements.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 ulcerative colitis topline data readout60% success
• Q4 2026Regulatory submission (FDA/EMA) for obefazimod in UC55% success
• TBDPotential licensing or partnership deal for obefazimod or pipeline40% success